title: Postthrombotic morbidity correlates with residual thrombus following catheter-directed thrombolysis for iliofemoral deep vein thrombosis.
abstract: BACKGROUND
  Iliofemoral deep vein thrombosis (DVT) is associated with severe postthrombotic morbidity when treated with anticoagulation alone. Catheter-directed thrombolysis (CDT), with or without the addition of mechanical techniques, is increasingly recommended for patients with iliofemoral DVT, although its effect on postthrombotic syndrome is not established. This study examined the correlation of residual thrombus with postthrombotic syndrome after catheter-based attempts at thrombus removal in patients with iliofemoral DVT.
  
  
  METHODS
  Seventy-one consecutive patients with iliofemoral DVT were treated with CDT. Pretreatment and posttreatment phlebograms were evaluated for quantity of residual thrombus by physicians blinded to clinical patient outcomes. Postthrombotic syndrome was assessed using CEAP and Villalta scores by examiners blinded to phlebographic results. Patients were grouped by the amount of residual thrombus in treated vein segments (group 1, ≤50%; group 2, >50%). Clinical score and postthrombotic outcomes were plotted vs residual thrombus.
  
  
  RESULTS
  Sixty-three of 71 patients completed CEAP and Villalta analyses. Groups 1 and 2 had median CEAP scores of 1 and 4 (P = .025) and mean Villalta scores of 2.21 and 7.13, respectively (P = .011). There was a direct and significant correlation of clinical class of CEAP with residual thrombus (R(2) = .74; P = .004) and a direct linear correlation of Villalta score with residual thrombus (R(2) = .61; P = .0014).
  
  
  CONCLUSIONS
  In patients with iliofemoral DVT treated with catheter-based techniques of thrombus removal, postthrombotic morbidity is related to residual thrombus. When thrombus clearance was complete, the postthrombotic syndrome was avoided. Residual thrombus is associated with an increasing risk of postthrombotic syndrome.
authors.affiliation: Jobst Vascular Institute, Toledo, OH 43606, USA.
authors.forename: Anthony J
authors.initials: AJ
authors.lastname: Comerota
authors.forename: Nina
authors.initials: N
authors.lastname: Grewal
authors.forename: Jorge Trabal
authors.initials: JT
authors.lastname: Martinez
authors.forename: John Tahao
authors.initials: JT
authors.lastname: Chen
authors.forename: Robert
authors.initials: R
authors.lastname: Disalle
authors.forename: Linda
authors.initials: L
authors.lastname: Andrews
authors.forename: Deb
authors.initials: D
authors.lastname: Sepanski
authors.forename: Zakaria
authors.initials: Z
authors.lastname: Assi
mesh_terms: D002404:Catheterization / Q000009:adverse effects; D005260:Female; D005268:Femoral Vein / Q000000981:diagnostic imaging; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007084:Iliac Vein / Q000000981:diagnostic imaging; D016014:Linear Models; D008297:Male; D061185:Mechanical Thrombolysis / Q000009:adverse effects; D008875:Middle Aged; D009820:Ohio; D010690:Phlebography; D054070:Postthrombotic Syndrome / Q000000981:diagnostic imaging / Q000209:etiology* / Q000517:prevention & control; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D015912:Thrombolytic Therapy / Q000009:adverse effects; D013997:Time Factors; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000150:complications / Q000000981:diagnostic imaging / Q000628:therapy*
chemical_list: D005343:Fibrinolytic Agents